Topical and Intralesional Treatment of Nonmelanoma Skin Cancer: Efficacy and Cost Comparisons
Authors:
- Jeremy EtzkornJEJeremy Etzkorn
- George CohenGCGeorge Cohen
- 1 September 2013
- journal article
- review article
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 39 (9) , 1306-1316
Abstract
Topical chemotherapy, topical immunomodulators, or intralesional chemotherapy may be used to treat nonmelanoma skin cancer (NMSC). To review the cost and efficacy of topical and intralesional therapies for NMSC. Literature search assessing the efficacy of NMSC treatment with topical imiquimod, topical 5-flourouracil (5FU) intralesional 5FU, methotrexate, bleomycin, and interferon (IFN). Single-lesion case reports were excluded. Aggregate cure rates and the estimated cost of treatment (including excision and repair of recurrent lesions) for a sample 1-cm lesion on an extremity were calculated. Cure rates ranged from 65% to 100% for topical imiquimod and 61% to 92% for 5FU. For intralesional agents, cure rates varied considerably according to medication used and NMSC subtype treated. Keratoacanthomas had high cure rates with intralesional agents: 98% for 5FU, 91% for methotrexate, 100% for bleomycin, 100% for IFN alpha (α)-2, 83% for IFN α-2a, and 100% for IFN α-2b. Estimated costs (excluding medication cost) ranged from $205 (intralesional methotrexate for keratoacanthoma) to $1,174 (IFN α-2a for superficial basal cell carcinoma). Nonsurgical management of NMSC remains a viable and relatively cost effective treatment option in select cases. Providers should consider the relative efficacy and cost of each medication when using nonsurgical modalities.Keywords
This publication has 55 references indexed in Scilit:
- Treatment of Keratoacanthoma with 5% Imiquimod Cream and Review of the Previous ReportAnnals of Dermatology, 2011
- A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinomaJournal of the American Academy of Dermatology, 2007
- Intralesional methotrexate treatment for keratoacanthoma tumors: A retrospective study and review of the literatureJournal of the American Academy of Dermatology, 2007
- Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinomaJournal of the American Academy of Dermatology, 2006
- Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapyJournal of the American Academy of Dermatology, 2006
- Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): A randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2006
- Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studiesJournal of the American Academy of Dermatology, 2004
- Large keratoacanthomas treated with intralesional interferon alfa-2aJournal of the American Academy of Dermatology, 1993
- Treatment of neoplastic skin lesions with intralesional interferonJournal of the American Academy of Dermatology, 1989
- Large keratoacanthomas in difficult locations treated with intralesional 5-fiuorouracilJournal of the American Academy of Dermatology, 1986